ERBB2 and neoplasm: To evaluate the therapeutic potential of FLAG‐CAR 4 T cells in combination with a tumor‐targeting FLAG‐tagged reagent, we engineered a recombinant protein consisting of an anti‐HER2 scFv fused to a FLAG tag as the core targeting element (Figure 7a).